Patents by Inventor Mustafa G. Mujtaba

Mustafa G. Mujtaba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of autophosphorylation protein kinases
    Patent number: 7189694
    Abstract: The subject invention concerns peptide molecules that specifically inhibit the enzymatic function of tyrosine kinases, including the JAK and EGF receptor (EGFR) family of kinases, to autophosphorylate, i.e., to transfer a phosphate group from ATP to an amino acid in the kinase. Phosphorylation of proteins is the most fundamental method for signal transduction among proteins in a cell. Inhibition of tyrosine kinase autophosphorylation activities inhibits the enzyme's signaling and shuts down the functioning pathways originating from the enzyme. The JAK2 and EGFR tyrosine kinases are involved in both inflammatory disorders and cancer. In these disorders, the tyrosine kinases can often be activated in an uncontrolled fashion. The subject application also concerns antibodies that bind to a tyrosine kinase autophosphorylation site.
    Type: Grant
    Filed: April 19, 2004
    Date of Patent: March 13, 2007
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Howard M. Johnson, Prem S. Subramaniam, Mustafa G. Mujtaba, Lawrence Flowers
  • Materials and methods for inhibition of IgE production
    Publication number: 20040131589
    Abstract: The subject invention concerns novel methods and materials for treating patients afflicted with allergic conditions, such as allergic rhinitis, atopic dermatitis, bronchial asthma and food allergy. The method of the subject invention comprises administering interferon tau (IFN&tgr;) or a chimeric IFN (ovine IFN&tgr; (1-27)/human IFN&agr;D (28-166)) to a person afflicted with an allergic condition. When administered, INF&tgr; and chimeric IFN suppress the production of IgE antibodies without toxic side effects. The subject invention also concerns chimeric ovine/human IFNs which can be used in the methods of the invention.
    Type: Application
    Filed: September 19, 2003
    Publication date: July 8, 2004
    Inventors: Howard M. Johnson, Mustafa G. Mujtaba
  • Materials and methods for treating autoimmune disease
    Patent number: 6403562
    Abstract: The subject invention pertains to novel methods for treating autoimmune-related diseases, such as Multiple Sclerosis (MS). One embodiment of the method of the invention comprises administering interleukin-10 (IL-10) and transforming growth factor-beta (TGF-&bgr;), in combination, to a person afflicted with or predisposed to an autoimmune disease. When administered in combination, these cytokines act in a synergistic manner as suppressor factors to inhibit the activation of self-reactive T cells that are involved in autoimmune disease.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: June 11, 2002
    Assignee: University of Florida
    Inventors: Howard M. Johnson, Mustafa G. Mujtaba, Jeanne M. Soos
  • Materials and methods for treating autoimmune disease
    Patent number: 6083919
    Abstract: The subject invention pertains to novel methods for treating autoimmune-related diseases, such as Multiple Sclerosis (MS). One embodiment of the method of the invention comprises administering interleukin-10 (IL-10) and transforming growth factor-beta (TGF-.beta.), in combination, to a person afflicted with or predisposed to an autoimmune disease. When administered in combination, these cytokines act in a synergistic manner as suppressor factors to inhibit the activation of self-reactive T cells that are involved in autoimmune disease.
    Type: Grant
    Filed: December 5, 1997
    Date of Patent: July 4, 2000
    Assignee: University of Florida
    Inventors: Howard M. Johnson, Mustafa G. Mujtaba, Jeanne M. Soos